Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Videos|July 23, 2018
Therapeutic Approach for IDH2-Mutated AML
Therapeutic Approach for IDH2-Mutated AML
Advertisement
Case: A 65-Year-Old Woman withIDH2-Mutated AML
November 2017
- A 65-year-old female was diagnosed with AML, normal cytogenetics;IDH2R140,RUNX1,andDNMT3Amutations
- 7+3 induction chemotherapy was initiated
- Her treatment course was complicated by mucositis and febrile neutropenia
- After resolution of her complications, she received 2 cycles of intermediate-dose cytarabine consolidation
May 2018
- Now, 6 months after her initial diagnosis, she presents with fatigue, aches, and gum bleeding
- Labs: leukocytosis, 20% circulating myeloblasts, ANC 450 cells/mL
- Bone marrow biopsy: hypercellular 80% blast, normal cytogenetics
- NGS: mutations inIDH2,RUNX1,andDNMT3A
Advertisement
Related to this article
The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5